Organisation paid for research Program year 2025 Source: CMS Open Payments

Charter Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$2,036,602

19 payments

Through program year 2025, Charter Research, LLC is reported as receiving $2,036,602 in research payments, across 19 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $1,573,295 11
2024 Research $413,472 3
2023 Research $14,303 1
2021 Research $12,700 2
2019 Research $22,833 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $1,916,982 10 payments
  2. AstraZeneca Pharmaceuticals LP $70,739 3 payments
  3. Celgene Corporation $13,000 1 payment
  4. Avanir Pharmaceuticals, Inc. $12,700 2 payments
  5. Eisai Inc. $11,583 1 payment
  6. AbbVie, Inc. $11,250 1 payment
  7. Novartis Pharmaceuticals Corporation $348 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $1,359,789 4 payments
  2. Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $358,785 2 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) $188,316 1 payment
  4. A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele $70,739 3 payments
  5. A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease $16,407 2 payments
  6. 20-Avp-786-307 $12,700 2 payments
  7. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $11,583 1 payment
  8. M16-100 $11,250 1 payment
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) $4,772 1 payment
  10. A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease $1,913 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record